$1.58
6.04% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

PepGen Stock price

$1.58
+0.06 3.95% 1M
-2.82 64.09% 6M
-2.21 58.31% YTD
-11.91 88.29% 1Y
-9.66 85.94% 3Y
-11.31 87.74% 5Y
-11.31 87.74% 10Y
NYSE, Closing price Tue, May 20 2025
+0.09 6.04%
ISIN
US7133171055
Symbol
PEPG
Sector
Industry

Key metrics

Market capitalization $51.70m
Enterprise Value $-27.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.33
P/B ratio (TTM) P/B ratio 0.56
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-109.26m
Free Cash Flow (TTM) Free Cash Flow $-83.34m
Cash position $97.78m
EPS (TTM) EPS $-3.14
P/E forward negative
Short interest 12.95%
Show more

Is PepGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

PepGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a PepGen forecast:

4x Buy
80%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a PepGen forecast:

Buy
80%
Sell
20%

Financial data from PepGen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 1.52 1.52
8% 8%
-
-1.52 -1.52
8% 8%
-
- Selling and Administrative Expenses 21 21
24% 24%
-
- Research and Development Expense 86 86
28% 28%
-
-108 -108
27% 27%
-
- Depreciation and Amortization 1.52 1.52
8% 8%
-
EBIT (Operating Income) EBIT -109 -109
26% 26%
-
Net Profit -102 -102
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about PepGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PepGen Stock News

Neutral
Business Wire
about 17 hours ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product a...
Neutral
Business Wire
13 days ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025. “Our EDO platform's unique ability to efficientl...
Neutral
Business Wire
about 2 months ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesd...
More PepGen News

Company Profile

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Head office United States
CEO James McArthur
Employees 81
Founded 2018
Website pepgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today